The discussion dives into the clinical use of exosomes compared to bone marrow stem cells, highlighting the latter's effectiveness in treating severe conditions. Insights reveal that placental stem cells, while considered advanced, have fragile telomeres that limit their longevity in the body. The conversation also touches on the legal landscape surrounding stem cell treatments in the U.S. and the reasons patients seek therapies abroad.
